The DOI matches its Crossref record; 75 of the 76 references it cites were found in a registry or an index.
Drug treatments in Alzheimer’s disease
Open accessAbstract
Despite the significant public health issue that it poses, only five medical treatments have been approved for Alzheimer's disease (AD) and these act to control symptoms rather than alter the course of the disease. Studies of potential disease-modifying therapy have generally been undertaken in patients with clinically detectable disease, yet evidence suggests that the pathological changes associated with AD begin several years before this. It is possible that pharmacological therapy may be beneficial in this pre-clinical stage before the neurodegenerative process is established. Techniques providing earlier diagnosis, such as cerebrospinal fluid biomarkers and amyloid positron emission tomography neuroimaging, are key to testing this theory in clinical trials. Recent results from trials of agents such as aducanumab are encouraging but must also be interpreted with caution. Such medicines could potentially delay the onset of dementia and would therefore markedly reduce its prevalence. However, we currently remain a good distance away from clinically available disease-modifying therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Current treatments for AD, including cholinesterase inhibitors and memantine, offer limited symptom relief, especially in the early to moderate stages, but do not halt disease progression or address the underlying neurodegeneration.”
From Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer’s Treatment: Systematic Review (2025) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Four drugs (donepezil, memantine, galantamine, rivastigmine) are approved on the market and belong to two families: anticholinesterase inhibitors and anti-glutaminergics.”
From Alzheimer's Disease: Treatment Strategies and Their Limitations. (2022) · cites this paper as [155]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
Ngandu, T., Lehtisalo, J., Solomon, A., Levälahti, E., Ahtiluoto, S., Antikainen, R., Bäckman, L., Hänninen, T., Jula, A., Laatikainen, T., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60461-5 · Cited by 3,689
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
Neuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345
Bloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194
Jack, C. R., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., Thies, B., & Phelps, C. H. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.004 · Cited by 2,042
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Research works printed but not linked: 1
- Mosconi, 2010, Pre-clinical detection of Alzheimer’s disease using FDG-PET, with or without amyloid imaging, J Alzheimers Dis, 20, 843, 10.3233/JAD-2010-091504 · DOI
Cited by
Sorted by citations
Items 301–400 of 576
Donepezil-based combination therapy for Alzheimer’s disease and related neuropathies
Ekundayo, B. E., Obafemi, T. O., Adewale, O. B., & Oyinloye, B. E. (2023) · Comparative Clinical Pathology · doi:10.1007/s00580-023-03487-w · Cited by 8
Yang, F., Zhang, N., Ou, G., & Xu, S.-W. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.5 · Cited by 11
Development of Serious Game Theory Framework in Virtual Reality for Alzheimer's Patients
Zuo, H., Lim, K. H., Eswaran, S., & Lease, B. A. (2024) · International Conference on Green Energy, Computing and Sustainable Technology (GECOST) · doi:10.1109/gecost60902.2024.10474644 · Cited by 8
Cannabinoids’ Role in Modulating Central and Peripheral Immunity in Neurodegenerative Diseases
Sharon, N., Yarmolinsky, L., Khalfin, B., Fleisher‐Berkovich, S., & Ben‐Shabat, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126402 · Cited by 9
Inflammasomes in Alzheimer’s Progression: Nrf2 as a Preventive Target
López-Hernández, R., de la Torre-Álamo, M. M., García-Bueno, B., Baroja‐Mazo, A., Fenoy, F. J., & Cuevas, S. (2025) · Antioxidants · doi:10.3390/antiox14020121 · Cited by 9
Quan, Q., Ma, X., Feng, J., Li, W., & Li, X. (2025) · Neuropeptides · doi:10.1016/j.npep.2025.102514 · Cited by 9
Cheng, X., Chen, H., Wang, J., & Pan, X. (2025) · Psychogeriatrics · doi:10.1111/psyg.70043 · Cited by 8
Szala‐Rycaj, J., Zagaja, M. P., Szewczyk, A., Polak, J., & Andres‐Mach, M. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47080635 · Cited by 10
Tian, S., Liu, Y., Hong, H., & Li, S. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05280-y · Cited by 8
Tambaro, S., Mitra, S., Gera, R., Linderoth, B., Wahlberg, L. U., Darreh‐Shori, T., Behbahani, H., Nilsson, P., & Eriksdotter, M. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01282-x · Cited by 9
Rothman, J. (2024) · Bilingualism Language and Cognition · doi:10.1017/s1366728924000026 · Cited by 8
Lin, F., Zhang, H., Bao, J., & Li, L. (2021) · World Neurosurgery · doi:10.1016/j.wneu.2021.06.118 · Cited by 8
Alzheimer’s Disease Treated with Autologous and Allogeneic TelomerasePositive Stem Cells
Young, W., & Speight, M. O. (2021) · Stem Cell & Regenerative Medicine · doi:10.33425/2639-9512.1058 · Cited by 8
Demand Coupling Drives Neurodegeneration: A Model of Age-Related Cognitive Decline and Dementia
Turknett, J., & Wood, T. R. (2022) · Cells · doi:10.3390/cells11182789 · Cited by 9
Wang, B. J., Liu, W., & Sun, F.-X. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1034766 · Cited by 8
The molecular pathology of neurodegenerative and psychiatric disorders
Yan, P., Deng, Y. M., Su, X., Kong, H., Zhang, Y., Li, W., & Kong, E. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18677-6.00007-5 · Cited by 8
Liu, Q. F., Kanmani, S., Lee, J., Kim, G.-W., Jeon, S., & Koo, B. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201614 · Cited by 8
Yin, Z., Li, X., Wang, L., Sun, M., Zhao, L., & Liang, F. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/3288948 · Cited by 8
Nirogi, R. V. S., Grandhi, V. R., Medapati, R. B., Ganuga, N., Abraham, R., Thentu, J. B., Palacharla, V. R. C., Petlu, S., Srirangavaram, M., Subramanian, R., et al. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175625 · Cited by 7
Targeting calciumopathy for neuroprotection: focus on calcium channels Cav1, Orai1 and P2X7
Torres-Rico, M., García-Calvo, V., Gironda-Martínez, A., Pascual-Guerra, J., Garcı́a, A. G., & Maneu, V. (2024) · Cell Calcium · doi:10.1016/j.ceca.2024.102928 · Cited by 8
Huang, X., Wang, J., Zhao, X., Sooranna, S. R., Liao, B., Jian, C., Shang, J., & Li, X. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.143196 · Cited by 7
RetractedHossain, M. M., Adhikari, J., & Shibly, A. Z. (2025) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2025.100095 · Cited by 7
Challenges and Opportunities of Drug Delivery for Treatment of Alzheimer’s Disease
El-Fattah, M. A. A. (2026) · AAPS PharmSciTech · doi:10.1208/s12249-025-03316-z · Cited by 9
Ding, Y., Peng, Y.-Y., Li, S., Tang, C. L., Gao, J., Wang, H., Long, Z.-Y., Lu, X., & Wang, Y. (2023) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-023-01207-3 · Cited by 7
Gardner, R. S., Kyle, M. M., Hughes, K., & Zhao, L. (2024) · Biomolecules · doi:10.3390/biom14070827 · Cited by 7
Chen, B., Mou, C., Guo, F.-Y., Sun, Q., Qu, L., Li, L., Cui, W., Lu, F., Jin, C. H., & Liu, F. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00771 · Cited by 7
Inoue, M., Higashi, T., Hayashi, Y., Onodera, R., Fujisawa, K., Taharabaru, T., Yokoyama, R., Ouchi, K., Misumi, Y., Ueda, M., et al. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c09913 · Cited by 7
Aducanumab: a review of the first approved amyloid-targeting antibody for Alzheimer’s disease
Grover, S., & Jain, S. (2022) · Drugs & Therapy Perspectives · doi:10.1007/s40267-022-00944-4 · Cited by 7
Alexandre-Silva, V., Pereira, G. C., & Ribeiro, A. M. (2023) · Oriental Pharmacy and Experimental Medicine · doi:10.1007/s13596-023-00696-0 · Cited by 7
Majumder, S., & George, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-19084-1.00001-6 · Cited by 8
Hu, X., Yamashita, T., Yu, H., Bian, Z., Hu, X., Feng, T., Tadokoro, K., Morihara, R., & Abe, K. (2021) · Neurodegenerative Diseases · doi:10.1159/000523983 · Cited by 7
Salleh, W. M. N. H. W., Shakri, N. M., Nafiah, M. A., Ghani, N. A., Abed, S. A., & Abdel‐Aal, A. M. (2023) · Bulletin of Pharmaceutical Sciences Assiut · doi:10.21608/bfsa.2023.300925 · Cited by 6
Nguyen‐Thi, P., Vo, T. K., Le, H. T., Nguyen, N. T. T., Nguyen, T. T., & Giau, V. V. (2024) · Pharmaceutical Research · doi:10.1007/s11095-024-03718-x · Cited by 6
Advanced intranasal peptide delivery systems for improved management of Alzheimer's disease
Majie, A., Karmakar, V., Ghosh, A., Chakraborty, S., Apurva, A., Layek, B., & Gorain, B. (2025) · Biomaterials Advances · doi:10.1016/j.bioadv.2025.214474 · Cited by 8
Güngör, Ö., & Köse, M. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.132817 · Cited by 6
Ameliorative Effect of Medicarpin on Scopolamine-Induced Cognitive Impairment in Mice
Oh, J., Park, J., Mun, S., Yee, S., & Kim, H. (2023) · Processes · doi:10.3390/pr11020385 · Cited by 6
Lingling, Tsuji, T., Ide, K., & Kondo, K. (2023) · Preventive Medicine · doi:10.1016/j.ypmed.2023.107573 · Cited by 6
Zhou, Y., Yang, H., You, M., Feng, Z., & Dong, X. (2024) · World Neurosurgery · doi:10.1016/j.wneu.2024.01.165 · Cited by 6
The Validity of a Smartphone-Based Application for Assessing Cognitive Function in the Elderly
Min, J., Kim, D., Jang, H., Kim, H., Kim, S., Lee, S., Seo, Y.-J., Kim, Y.-J., Kim, J.-Y., & Min, K. (2025) · Diagnostics · doi:10.3390/diagnostics15010092 · Cited by 6
Aksöz, B. E., & Aksöz, E. (2020) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207323666200220115154 · Cited by 6
Darbà, J., & Marsà, A. (2020) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2020.1820328 · Cited by 6
da Silva, U. P., de Sousa, B. L., Agrizzi, A. P., Mantovani, H. C., Leite, J. P. V., & Varejão, E. V. V. (2021) · South African Journal of Botany · doi:10.1016/j.sajb.2021.07.009 · Cited by 6
Zunyimycin C enhances immunity and improves cognitive impairment and its mechanism
Wang, X., Li, Z., Sun, R. X., Li, X., Guo, R., Cui, X., Liu, B., Li, W., Yang, Y., Huang, X., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.1081243 · Cited by 6
Mahmoud, Z., Mohamed, L. W., Mohamed, K. O., Sayed, H. S., Fattah, M. A. A. E., & El-Malah, A. A. (2023) · Medicinal Chemistry Research · doi:10.1007/s00044-022-03013-7 · Cited by 6
Rai, A., Ojiakor, O. A., & Rylett, R. J. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15904 · Cited by 6
Wang, Y., Cao, Y., Huang, H., Xue, Y., Chen, S., & Gao, X. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109863 · Cited by 6
Zhang, W., Zhu, F., Zhu, J., & Liu, K. (2024) · Analytical Cellular Pathology · doi:10.1155/2024/6681911 · Cited by 6
Unraveling the dual role of ADAM10: Bridging the gap between cancer and Alzheimer’s disease
Alexandre-Silva, V., & Cominetti, M. R. (2024) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2024.111928 · Cited by 7
Moxibustion for the treatment of Alzheimer's disease
Rigun, A., Yue, R., Chen, B., & Huang, X. (2021) · Medicine · doi:10.1097/md.0000000000024657 · Cited by 6
Acetylcholinesterase inhibitors and nanoparticles on Alzheimer’s disease: a review
Silva, S., Almeida, A. J., & Vale, N. (2021) · Journal of Nanoparticle Research · doi:10.1007/s11051-020-05118-9 · Cited by 6
Cerebrovascular disease and dementia
Waller, D. G., & Sampson, A. P. (2017) · Elsevier eBooks · doi:10.1016/b978-0-7020-7167-6.00009-9 · Cited by 6
Yan, L., Xu, K., Liu, C., Feng, Y., Guo, J., Hou, L., Feng, Y., Yang, M., Gong, Q., Qin, D., et al. (2024) · Advanced Materials · doi:10.1002/adma.202412843 · Cited by 5
Yang, Z. X., Sheng, J., Zhang, Q., Zhao, X., Song, Y., Dong, G., Zhang, R., Zhao, H., Wang, J., Pan, R., et al. (2025) · Journal of Integrative Neuroscience · doi:10.31083/jin26584 · Cited by 7
Liu, C., Zhao, Y., Dao, J.-J., Zhang, W., Liu, J., Ma, Y.-K., Qiao, C.-M., Cui, C., Chen, S., Shen, Y., et al. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00739 · Cited by 5
Climacosa, F. M. M., Anlacan, V. M. M., Gordovez, F. J. A., Reyes, J. C. B., Tabios, I. K. B., Manalo, R. V. M., Cruz, J. M. C., Asis, J. L. B., Razal, R. B., Abaca, M. J. M., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-078660 · Cited by 5
Ren, R., Zhang, G., Ma, J., Zheng, Y., Zhao, Y., Zhang, Y., & Zhao, L. (2025) · Scientific Reports · doi:10.1038/s41598-025-89747-x · Cited by 5
Bhattacharjee, P., & Bhattacharyya, D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141986 · Cited by 5
Tang, L., Jiang, J., Song, G., Wang, Y., Zhuang, Z., Tan, Y., Xia, Y., Huang, X., & Feng, X. (2021) · Scientific Reports · doi:10.1038/s41598-021-03194-y · Cited by 6
Amyloid Beta Dynamics in Biological Fluids—Therapeutic Impact
Schreiner, T. G., & Popescu, B. O. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10245986 · Cited by 5
Fan, F., & Chen, C. (2024) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2024051776 · Cited by 6
Phyto-nanotechnology: A novel beneficial strategy for Alzheimer's disease therapy
Ganguly, S. C., Sangram, S., Paul, S., & Kundu, M. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105868 · Cited by 5
Stenn, D. F. (2026) · The Atrium (University of Guelph) · doi:10.3390/ph18050659
Lipid nanocarriers encapsulating herbal drugs for brain diseases therapy
Gad, S., El-Gogary, R. I., Geneidi, A. S., & Hathout, R. M. (2023) · Archives of Pharmaceutical Sciences Ain Shams University · doi:10.21608/aps.2023.202432.1115 · Cited by 5
Utilizing MCID for evaluating clinical relevance of AD therapeutic interventions
Hamilton, J. L., Fuller, R. L. M., Modi, N., & Sampaio, C. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70138 · Cited by 4
Zhang, X., Sun, Z., Wu, D.-W., Shi, X., Song, C., Guan, X., Hao, J., Guo, Y., Wang, X., Wei, D., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251366656 · Cited by 4
Gautam, A. S., Akhtar, M. Z., Lasure, V., Kumari, N., Pandey, S. K., Dey, M., & Singh, R. K. (2025) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-025-10246-x · Cited by 4
Zhang, R., Huang, X., Zhou, C., Zhang, Q., Jia, D., Xie, X., & Zhang, J. (2024) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-024-04589-w · Cited by 4
Goel, K. K., Chahal, S., Kumar, D., Jaiswal, S., Nainwal, N., Singh, R. K., Mahajan, S., Rawat, P., Yadav, S., Fartyal, P., et al. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00461b · Cited by 4
Kandeda, A. K., Mezui, C., Kengni, S., Baldagai, N., & Mabou, S. T. (2025) · Brain and Behavior · doi:10.1002/brb3.70261 · Cited by 4
Wang, J., Pan, H., Tang, H., Zhang, J., Li, T., Liu, Y., Huang, Y., Fei, Z., & Wang, Y. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.119642 · Cited by 4
Modeling Alzheimer's disease using cerebral organoids: Current challenges and prospects
Abijo, A. Z., Olatunji, S., Adelodun, S. T., Asamu, M. O., & Omeiza, N. A. (2024) · Brain Organoid and Systems Neuroscience Journal · doi:10.1016/j.bosn.2024.09.001 · Cited by 6
Lee, S., Lim, C. K., Kim, J., Kim, J., Jin, H. K., Bae, J., & Jeon, J.-W. (2025) · Biomedicines · doi:10.3390/biomedicines13051169 · Cited by 4
Nathan, A. B. P., Aziz, A., Choi, S. M., Lee, S. H., Jeon, S., Kim, H.-S., Cho, J. H., & Jo, J. (2025) · Cells · doi:10.3390/cells14110826 · Cited by 4
Radwan, A. A., & Alanazi, F. K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073546 · Cited by 4
Elexpe, A., Sánchez-Sánchez, L., Tolentino‐Cortez, T., Astigarraga, E., Torrecilla, M., & Barreda‐Gómez, G. (2022) · Biomedicines · doi:10.3390/biomedicines10050980 · Cited by 4
Role of Computational Modeling in Drug Discovery for Alzheimer’s Disease
Yadav, M. R., Murumkar, P. R., Barot, R. R., Yadav, R., Joshi, K. D., & Chauhan, M. (2023) · Challenges and advances in computational chemistry and physics · doi:10.1007/978-3-031-33871-7_3 · Cited by 5
ElMosbah, D. E., Khattab, M. S., Ibrahim, M. A., Khalil, H. M. A., El-Assal, M. I. A., & Miniawy, H. M. F. E. (2024) · Egyptian Journal of Veterinary Science · doi:10.21608/ejvs.2024.260943.1768 · Cited by 4
Khabiya, R., Karati, D., Dwivedi, S., Dwivedi, A., & Mukherjee, S. (2024) · Brain Disorders · doi:10.1016/j.dscb.2024.100125 · Cited by 4
Acupuncture therapy for Alzheimer's disease
Wang, L., Xu, J., Zhan, Y., & Pei, J. (2020) · Medicine · doi:10.1097/md.0000000000020244 · Cited by 4
Natural Plant‐Derived Acetylcholinesterase Inhibitors: Relevance for Alzheimer's Disease
Braidy, N., Poljak, A., Jayasena, T., & Sachdev, P. S. (2017) · Wiley eBooks · doi:10.1002/9783527805921.ch12 · Cited by 5
Caporlingua, M., Castellano, J., Quartarone, A., & Ciurleo, R. (2025) · Neurology International · doi:10.3390/neurolint17120196 · Cited by 3
Xu, B., Sun, G., & Zhang, Y. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.138698 · Cited by 3
Resolution of the Expert Council on the problem of early diagnosis of Alzheimer's disease
Bogolepova, A. N., Васенина, Е. Е., Васильевна, В. Н., Vorobyеv, S. V., Si, G., Emelin, А. Y., Zakharov, V. V., Illarioshkin, S. N., Kosivtsova, O. V., Kostyuk, G. P., et al. (2024) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2024-5-111-119 · Cited by 3
Tan, K. M. W. Y. (2024) · Games for Health Journal · doi:10.1089/g4h.2024.0025 · Cited by 4
Bansal, N., Parvez, M. K., Babu, M. A., Al-Dosari, M. S., Singh, T. G., Ali, N., Tyagi, Y., Dadwal, A., Yadav, U. P., & Dwivedi, A. R. (2025) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2025.109036 · Cited by 3
Reevaluating Alzheimer’s disease treatment: Can phytochemicals bridge the therapeutic Gap?
Roy, K. K., Mehta, D. K., & Das, R. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.04.014 · Cited by 3
Yang, W., Yu, Q., Wang, N., Lam, K. K. Y., Lin, Z., & Xian, Y. (2025) · NeuroMolecular Medicine · doi:10.1007/s12017-025-08860-2 · Cited by 4
Saini, M., Rohilla, S., & Kumar, R. (2025) · Current Aging Science · doi:10.2174/0118746098376646250715094707 · Cited by 3
Aletaha, N., Dehghan, G., Sadeghi, L., Rashtbari, S., & Khataee, A. (2023) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2023.121547 · Cited by 3
Iwasa, K., Yagishita, S., Yagishita-Kyo, N., Yamagishi, A., Yamamoto, S., Yamashina, K., Haruta, C., Asai, M., Maruyama, K., Shimizu, K., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-44098-3 · Cited by 3
Imaging spectrum of amyloid-related imaging abnormalities associated with aducanumab immunotherapy
Sotoudeh, H., Alizadeh, M., Shahidi, R., Shobeiri, P., Saadatpour, Z., Wheeler, C. A., Love, M. N., & Tanwar, M. (2024) · Frontiers in Radiology · doi:10.3389/fradi.2023.1305390 · Cited by 4
Zhang, J., Li, Q., Yan, B., Wang, Q., & Zhou, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e26643 · Cited by 3
Studies on the mechanisms of action of MR33317
Neumann, J., Hesse, C., Yahiaoui, S., Dallemagne, P., Rochais, C., Hofmann, B., & Gergs, U. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03226-0 · Cited by 3
Cognitive Assessment and Early Detection of Alzheimer's disease
Deena, G., Karunakaran, N. B., Sharma, S., Pandey, V., & Nishant, N. (2024) · Advances in medical technologies and clinical practice book series · doi:10.4018/979-8-3693-3605-2.ch025 · Cited by 3
Oligonucleotide therapeutics for neurodegenerative diseases
Li, V. C., & Huang, Y. (2024) · NeuroImmune Pharmacology and Therapeutics · doi:10.1515/nipt-2024-0013 · Cited by 3
Hou, Q., & Li, Y. (2025) · Molecular Diversity · doi:10.1007/s11030-024-11061-x · Cited by 3
Polo-Cuadrado, E., Rojas-Peña, C., Acosta-Quiroga, K., Camargo-Ayala, L., Rodríguez‐Núñez, Y. A., Osorio, E. H., López, J. J., Rhonny, B.-C., & Gutiérrez, M. (2025) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2025.100270 · Cited by 3
Jenkins, K., Mateeva, T., Szabó, I., Melnik, A., Picotti, P., Csikász‐Nagy, A., & Rosta, E. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.04.010 · Cited by 3
The Role of Curcumin in Post-Ischemic Brain
Rusek, M., & Czuczwar, S. J. (2021) · Exon Publications eBooks · doi:10.36255/exonpublications.cerebralischemia.2021.curcumin · Cited by 3
Kłosińska, U., & Leszko, M. (2022) · Journal of Drug Issues · doi:10.1177/00220426221145019 · Cited by 3
Metadata
- Authors
- Briggs, R., Kennelly, S. P., & O’Neill, D.
- Affiliations
- Tallaght University Hospital (IE)
- Venue
- Clinical Medicine
- Publisher
- Elsevier BV
- Published
- 2016-06
- Volume
- 16
- Issue
- 3
- Pages
- 247-253
- ISSN
- 1470-2118 (ISSN-L)
- PMC
- PMC5922703
- OpenAlex
- W2415242066
- Cited by
- 571
- References
- 76
- Citations by year
- 2026: 37 · 2025: 67 · 2024: 97 · 2023: 79 · 2022: 106 · 2021: 95 · 2020: 55 · 2019: 18 · 2018: 5 · 2017: 9 · 2016: 2
- FWCI
- 9.13
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical Medicine (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, pharmacotherapy, disease-modifying therapy, symptomatic treatment, preclinical Alzheimer's disease, cerebrospinal fluid biomarkers, amyloid PET, aducanumab, early diagnosis, dementia prevention
- MeSH terms
- Alzheimer Disease, Amyloid, Cholinesterase Inhibitors, Humans, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
